THE ROLE, EFFECTIVENESS, AND SAFETY OF PHARMACOTHERAPY IN EATING DISORDERS (ANOREXIA NERVOSA, BULIMIA NERVOSA, BINGE EATING DISORDER, AND SLEEP-RELATED EATING DISORDER): A REVIEW OF CURRENT EVIDENCE AND META-ANALYSES
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.5168Keywords:
Eating Disorders, Pharmacotherapy, Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorders, Sleep-related Eating Disorders, Psychopharmacology, Adjunctive TreatmentAbstract
Eating disorders (EDs), including anorexia nervosa, bulimia nervosa, binge eating disorder and sleep-related eating disorder are complex psychiatric conditions with multifactorial determinants. Psychotherapy and structured nutritional rehabilitation remain the cornerstone of treatment, while pharmacotherapy serves an adjunctive role to address core symptoms, comorbid psychiatric conditions, and behavioral dysregulation.
In adults, selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine, are effective for reducing binge-purge behaviors in BN, with doses up to 60 mg/day. Lisdexamfetamine is FDA-approved for moderate-to-severe BED, reducing binge frequency via dopaminergic and noradrenergic pathways. Topiramate can reduce binge eating and promote modest weight loss but is limited by cognitive and gastrointestinal side effects. In AN, pharmacotherapy is largely adjunctive, atypical antipsychotics such as olanzapine may modestly improve weight and pre-meal anxiety, while SSRIs mainly address mood symptoms post-weight restoration. Sleep Related Eating Disorders management involves SSRIs, topiramate, and clonazepam, alongside treatment of underlying sleep disorders.
In children and adolescents, pharmacotherapy evidence is limited. SSRIs show minimal efficacy for core AN symptoms and are mainly used for comorbid anxiety or depression. Fluoxetine may reduce binge-purge behaviors in adolescent BN when combined with psychotherapy, and olanzapine can offer modest benefit, though metabolic and sedation risks require monitoring.
Overall, pharmacotherapy enhances symptom management and engagement when integrated with psychotherapy and nutritional rehabilitation but is not a standalone treatment. Careful selection, dosing, and monitoring are essential to balance efficacy with potential adverse effects. Ongoing research is needed to clarify pharmacological strategies in AN, pediatric populations, and treatment-resistant EDs.
References
Beykloo, M. Y. (2021). Pharmacotherapy in anorexia nervosa [Doctoral dissertation, University College London]. UCL Discovery. https://discovery.ucl.ac.uk/id/eprint/10129953
Chiaro, G., Caletti, M. T., & Provini, F. (2015). Treatment of sleep-related eating disorder. Current Treatment Options in Neurology, 17, 33. https://doi.org/10.1007/s11940-015-0361-6
Costa, G. P. A., Assunção, B. R., Belfort-DeAguiar, R., & Nunes, J. C. (2025). Pharmacotherapies for binge eating disorder: Systematic review and network meta-analysis. Obesity Reviews, 26(9), e13936. https://doi.org/10.1111/obr.13936
Couturier, J., & Lock, J. (2007). A review of medication use for children and adolescents with eating disorders. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 16(4), 173–176. https://pubmed.ncbi.nlm.nih.gov/18392170/
Çöpür, S., & Çöpür, M. (2020). Olanzapine in the treatment of anorexia nervosa: A systematic review. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 56, 60. https://doi.org/10.1186/s41983-020-00195-y
Frank, B., Arnold, S., Jaite, C., & Correll, C. U. (2023). Antipsychotic effects on anthropometric outcomes in anorexia nervosa: A retrospective chart review of hospitalized children and adolescents. Journal of Eating Disorders, 11, 151. https://doi.org/10.1186/s40337-023-00862-4
Garner, D. M., Anderson, M. L., Keiper, C. D., Whynott, R., & Parker, L. (2016). Psychotropic medications in adult and adolescent eating disorders: Clinical practice versus evidence-based recommendations. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 21, 395–402. https://doi.org/10.1007/s40519-016-0253-0
Ghaderi, A., Odeberg, J., Gustafsson, S., Råstam, M., Brolund, A., Pettersson, A., & Parling, T. (2018). Psychological, pharmacological, and combined treatments for binge eating disorder: A systematic review and meta-analysis. PeerJ, 6, e5113. https://doi.org/10.7717/peerj.5113
Han, R., Bian, Q., & Chen, H. (2022). Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta-analysis. Brain and Behavior, 12(2), e2498. https://doi.org/10.1002/brb3.2498
Himmerich, H., Lewis, Y. D., Conti, C., Mutwalli, H., Karwautz, A., Sjögren, J. M., Uribe Isaza, M. M., Tyszkiewicz-Nwafor, M., Aigner, M., McElroy, S. L., Treasure, J., Kasper, S., Bailer, U., Bulik, C. M., De Zwaan, M., Favaro, A., Fernandez-Aranda, F., Fetissov, S., Hilbert, A., ... Yoshiuchi, K. (2023). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. The World Journal of Biological Psychiatry, 24(8), 643–706. https://doi.org/10.1080/15622975.2023.2179663
Jackson, C. W., Cates, M., & Lorenz, R. (2010). Pharmacotherapy of eating disorders. Nutrition in Clinical Practice, 25(2), 143–159. https://doi.org/10.1177/0884533610362239
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D. E., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015). Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: A randomized clinical trial. JAMA Psychiatry, 72(3), 235–246. https://doi.org/10.1001/jamapsychiatry.2014.2162
Muratore, A. F., & Attia, E. (2022). Psychopharmacologic management of eating disorders. Current Psychiatry Reports, 24, 345–351. https://doi.org/10.1007/s11920-022-01340-5
Norris, M. L., Spettigue, W., Buchholz, A., Henderson, K. A., Gomez, R., Maras, D., Gaboury, I., & Ni, A. (2011). Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. Journal of Child and Adolescent Psychopharmacology, 21(3), 213–220. https://doi.org/10.1089/cap.2010.0131
Reas, D. L., & Grilo, C. M. (2012). Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity, 16(9), 2024–2038. https://doi.org/10.1038/oby.2008.333
Rodan, S. C., Bryant, E., Le, A., Maloney, D., Touyz, S., McGregor, I. S., Maguire, S., & National Eating Disorder Research Consortium. (2023). Pharmacotherapy, alternative and adjunctive therapies for eating disorders: Findings from a rapid review. Journal of Eating Disorders, 11, 112. https://doi.org/10.1186/s40337-023-00833-9
Thorey, S., Blanchet, C., Guessoum, S. B., Moro, M. R., Ludot, M., & Carretier, E. (2023). Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review. PLOS ONE, 18(3), e0278189. https://doi.org/10.1371/journal.pone.0278189
Whittal, M. L., Agras, W. S., & Gould, R. A. (1999). Bulimia nervosa: A meta-analysis of psychosocial and pharmacological treatments. Behavior Therapy, 30(1), 117–135. https://doi.org/10.1016/S0005-7894(99)80049-5
Yu, S., Zhang, Y., Shen, C., & Shao, F. (2023). Efficacy of pharmacotherapies for bulimia nervosa: A systematic review and meta-analysis. BMC Pharmacology and Toxicology, 24, 72. https://doi.org/10.1186/s40360-023-00713-7
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Marcin Patryk Barbachowski, Natalia Bylak, Bruno Makowski, Oliwia Marciniak, Sebastian Konecki, Grzegorz Jałoszyński, Norbert Gromadzki, Maria Kurt, Anna Gwizdek, Maciej Makarewicz, Dawid Szczepański
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
